For the past four years, Takeda's plans for a full-scale entry into India have remained just that – plans on paper. But will it be a laggard for much longer in this fast-changing key emerging market? There are signs that the time may now be ripe for Japan's top pharma firm to take a more decisive plunge.
Takeda has said for years that strengthening its business platform in India remains a key objective. But despite this apparent...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
